Journal article
The prevalence of overtreatment of osteoporosis: results from the PAADRN trial
Archives of osteoporosis, Vol.13(1), pp.103-103
09/28/2018
DOI: 10.1007/s11657-018-0517-6
PMID: 30267162
Abstract
A Summary Overtreatment of osteoporosis increases costs and puts patients at unnecessary risk of experiencing adverse drug events. In the Patient Activation After DXA Receipt Notification (PAADRN) trial, we found that 8% of individuals with no indication for therapy were recommended a new osteoporosis medication or continuation of an existing medication.
Purpose There is a robust body of literature addressing undertreatment in osteoporosis, but limited data addressing overtreatment. Understanding overtreatment is important to minimize harm and decrease costs.
Methods One of the pre-specified post hoc analyses of the PAADRN trial, a randomized, controlled, pragmatic clinical trial, was to quantify and identify risk factors associated with osteoporosis overtreatment. PAADRN included patients >= 50 years of age presenting for bone density testing between February, 2012, and August, 2014, at three US healthcare systems. We assessed 20,397 patients for eligibility and randomized 7749. Intervention patients received a tailored letter containing their dual-energy X-ray absorptiometry (DXA) results and an educational osteoporosis brochure. Control patients received usual care. Using the National Osteoporosis Foundation treatment guidelines, we defined overtreatment as the receipt of osteoporosis pharmacotherapy 12 weeks after DXA when treatment was not indicated. We evaluated the relationship between the following baseline variables-sex, race/ethnicity, educational attainment, and differences across health systems-and overtreatment using a series of multivariable logistic regression models.
Results Among 3602 patients with no apparent indication for osteoporosis treatment, 292 (8.1%; 95% CI, 7.22 to 9.00%) received a new prescription for osteoporosis pharmacotherapy or were instructed to continue an existing medication (presumed overtreatment). Presumed overtreatment was more common among participants with prior DXA history, those who reported a history of osteoporosis or low bone mass, and those referred for testing by family medicine providers.
Conclusion In our sample of older adults, overuse of osteoporosis pharmacotherapy was only 8.1%. Nevertheless, overtreatment exposes patients to possible risk with negligible chance of benefit and should be minimized.
Details
- Title: Subtitle
- The prevalence of overtreatment of osteoporosis: results from the PAADRN trial
- Creators
- Sylvie F. Hall - Cleveland ClinicNicole C. Wright - University of Alabama at BirminghamFredric D. Wolinsky - Roy J. and Lucille A. Carver College of MedicineYiyue Lou - University of IowaStephanie Edmonds - Roy J. and Lucille A. Carver College of MedicineDouglas Roblin - Kaiser PermanenteMichael Jones - University of IowaKenneth Saag - University of Alabama at BirminghamPeter Cram - University of Toronto
- Resource Type
- Journal article
- Publication Details
- Archives of osteoporosis, Vol.13(1), pp.103-103
- Publisher
- Springer Nature
- DOI
- 10.1007/s11657-018-0517-6
- PMID
- 30267162
- ISSN
- 1862-3522
- eISSN
- 1862-3514
- Number of pages
- 10
- Grant note
- K12HS023009 / AGENCY FOR HEALTHCARE RESEARCH AND QUALITY; United States Department of Health & Human Services; Agency for Healthcare Research & Quality 1K12HS023009-01 / AHRQ; United States Department of Health & Human Services; Agency for Healthcare Research & Quality K24 AR062133; K24 AR052361 / NIAMS at the NIH K12 HS023009 / AHRQ; United States Department of Health & Human Services; Agency for Healthcare Research & Quality K24AR062133 / NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) R01 AG033035 / NIA at NIH
- Language
- English
- Date published
- 09/28/2018
- Academic Unit
- Statistics and Actuarial Science; Health Management and Policy; Biostatistics; Nursing; Public Policy Center (Archive)
- Record Identifier
- 9984283853202771
Metrics
8 Record Views